Epidermoid carcinoma of the anal canal

Bart C H van der Wal, Berry I. Cleffken, Gulec Bulent, Howard S. Kaufman, Michael A. Choti

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Epidermoid cancer of the anal canal is uncommon and occurs in the portion of the anus that runs from the anorectal ring to the anal verge. These tumors cause bleeding and pain and almost all can be identified by visual, digital, or anoscopic exam. Current initial treatment uses combination chemoradiotherapy. The radiotherapy entails 30 Gy (given over 3 to 4 weeks) using apposed fields with an additional boost of 15 to 20 Gy delivered to sites of macroscopic disease. Chemotherapy is given at the same time as the radiotherapy according to the following scheme: intravenous 5-FU (1000 mg/m2/day) on day 1 to 5 and day 31 to 35 and mitomycin C (15 mg/m2) on day 1. Patients undergo an evaluation to include visual inspection of the lesion site 1 month after completion of the radiotherapy. Any suspicious finding warrants a biopsy. Following chemoradiation, patients are examined every 3 months for the first 2 years, every 6 months for year 3 to 4, and yearly thereafter. An abdominoperineal resection or, in highly selected situations, additional chemoradiotherapy is offered to those patients with residual or recurrent disease following chemoradiation.

Original languageEnglish (US)
Pages (from-to)263-270
Number of pages8
JournalClinics in Colon and Rectal Surgery
Volume15
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Anal Canal
Squamous Cell Carcinoma
Radiotherapy
Chemoradiotherapy
Mitomycin
Fluorouracil
Neoplasms
Hemorrhage
Biopsy
Drug Therapy
Pain
Therapeutics

Keywords

  • Cloacogenic carcinoma
  • Epidermoid cancer
  • Squamous cell cancer

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

van der Wal, B. C. H., Cleffken, B. I., Bulent, G., Kaufman, H. S., & Choti, M. A. (2002). Epidermoid carcinoma of the anal canal. Clinics in Colon and Rectal Surgery, 15(4), 263-270. https://doi.org/10.1055/s-2002-36508

Epidermoid carcinoma of the anal canal. / van der Wal, Bart C H; Cleffken, Berry I.; Bulent, Gulec; Kaufman, Howard S.; Choti, Michael A.

In: Clinics in Colon and Rectal Surgery, Vol. 15, No. 4, 2002, p. 263-270.

Research output: Contribution to journalReview article

van der Wal, BCH, Cleffken, BI, Bulent, G, Kaufman, HS & Choti, MA 2002, 'Epidermoid carcinoma of the anal canal', Clinics in Colon and Rectal Surgery, vol. 15, no. 4, pp. 263-270. https://doi.org/10.1055/s-2002-36508
van der Wal BCH, Cleffken BI, Bulent G, Kaufman HS, Choti MA. Epidermoid carcinoma of the anal canal. Clinics in Colon and Rectal Surgery. 2002;15(4):263-270. https://doi.org/10.1055/s-2002-36508
van der Wal, Bart C H ; Cleffken, Berry I. ; Bulent, Gulec ; Kaufman, Howard S. ; Choti, Michael A. / Epidermoid carcinoma of the anal canal. In: Clinics in Colon and Rectal Surgery. 2002 ; Vol. 15, No. 4. pp. 263-270.
@article{34c3f00411a94a7facd3994641d50c10,
title = "Epidermoid carcinoma of the anal canal",
abstract = "Epidermoid cancer of the anal canal is uncommon and occurs in the portion of the anus that runs from the anorectal ring to the anal verge. These tumors cause bleeding and pain and almost all can be identified by visual, digital, or anoscopic exam. Current initial treatment uses combination chemoradiotherapy. The radiotherapy entails 30 Gy (given over 3 to 4 weeks) using apposed fields with an additional boost of 15 to 20 Gy delivered to sites of macroscopic disease. Chemotherapy is given at the same time as the radiotherapy according to the following scheme: intravenous 5-FU (1000 mg/m2/day) on day 1 to 5 and day 31 to 35 and mitomycin C (15 mg/m2) on day 1. Patients undergo an evaluation to include visual inspection of the lesion site 1 month after completion of the radiotherapy. Any suspicious finding warrants a biopsy. Following chemoradiation, patients are examined every 3 months for the first 2 years, every 6 months for year 3 to 4, and yearly thereafter. An abdominoperineal resection or, in highly selected situations, additional chemoradiotherapy is offered to those patients with residual or recurrent disease following chemoradiation.",
keywords = "Cloacogenic carcinoma, Epidermoid cancer, Squamous cell cancer",
author = "{van der Wal}, {Bart C H} and Cleffken, {Berry I.} and Gulec Bulent and Kaufman, {Howard S.} and Choti, {Michael A.}",
year = "2002",
doi = "10.1055/s-2002-36508",
language = "English (US)",
volume = "15",
pages = "263--270",
journal = "Clinics in Colon and Rectal Surgery",
issn = "1531-0043",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Epidermoid carcinoma of the anal canal

AU - van der Wal, Bart C H

AU - Cleffken, Berry I.

AU - Bulent, Gulec

AU - Kaufman, Howard S.

AU - Choti, Michael A.

PY - 2002

Y1 - 2002

N2 - Epidermoid cancer of the anal canal is uncommon and occurs in the portion of the anus that runs from the anorectal ring to the anal verge. These tumors cause bleeding and pain and almost all can be identified by visual, digital, or anoscopic exam. Current initial treatment uses combination chemoradiotherapy. The radiotherapy entails 30 Gy (given over 3 to 4 weeks) using apposed fields with an additional boost of 15 to 20 Gy delivered to sites of macroscopic disease. Chemotherapy is given at the same time as the radiotherapy according to the following scheme: intravenous 5-FU (1000 mg/m2/day) on day 1 to 5 and day 31 to 35 and mitomycin C (15 mg/m2) on day 1. Patients undergo an evaluation to include visual inspection of the lesion site 1 month after completion of the radiotherapy. Any suspicious finding warrants a biopsy. Following chemoradiation, patients are examined every 3 months for the first 2 years, every 6 months for year 3 to 4, and yearly thereafter. An abdominoperineal resection or, in highly selected situations, additional chemoradiotherapy is offered to those patients with residual or recurrent disease following chemoradiation.

AB - Epidermoid cancer of the anal canal is uncommon and occurs in the portion of the anus that runs from the anorectal ring to the anal verge. These tumors cause bleeding and pain and almost all can be identified by visual, digital, or anoscopic exam. Current initial treatment uses combination chemoradiotherapy. The radiotherapy entails 30 Gy (given over 3 to 4 weeks) using apposed fields with an additional boost of 15 to 20 Gy delivered to sites of macroscopic disease. Chemotherapy is given at the same time as the radiotherapy according to the following scheme: intravenous 5-FU (1000 mg/m2/day) on day 1 to 5 and day 31 to 35 and mitomycin C (15 mg/m2) on day 1. Patients undergo an evaluation to include visual inspection of the lesion site 1 month after completion of the radiotherapy. Any suspicious finding warrants a biopsy. Following chemoradiation, patients are examined every 3 months for the first 2 years, every 6 months for year 3 to 4, and yearly thereafter. An abdominoperineal resection or, in highly selected situations, additional chemoradiotherapy is offered to those patients with residual or recurrent disease following chemoradiation.

KW - Cloacogenic carcinoma

KW - Epidermoid cancer

KW - Squamous cell cancer

UR - http://www.scopus.com/inward/record.url?scp=0036870001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036870001&partnerID=8YFLogxK

U2 - 10.1055/s-2002-36508

DO - 10.1055/s-2002-36508

M3 - Review article

AN - SCOPUS:0036870001

VL - 15

SP - 263

EP - 270

JO - Clinics in Colon and Rectal Surgery

JF - Clinics in Colon and Rectal Surgery

SN - 1531-0043

IS - 4

ER -